|Bid||66.80 x 1100|
|Ask||66.81 x 900|
|Day's range||66.22 - 66.89|
|52-week range||52.65 - 71.70|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||104.23|
|Forward dividend & yield||1.45 (2.19%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties Agreement further substantiates C4XD's scientific expertise and strategy through a third significant deal with a major pharmaceutical company MANCHESTER, United Kingdom, Nov. 28, 2022 (GLOBE NEWSWIRE) -- C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with
AstraZeneca (Thailand) Co., Ltd., was recently honoured with two accolades in the categories of Industry Champions of the Year and Community Initiative at the Asia Corporate Excellence & Sustainability Awards 2022 (ACES Awards 2022).
WILMINGTON, Del., November 22, 2022--AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022.